Benefits of Renin-Angiotensin Blockade on Retinopathy in Type 1 Diabetes Vary With Glycemic Control

OBJECTIVE: Optimal glycemic control slows diabetic retinopathy (DR) development and progression and is the standard of care for type 1 diabetes. However, these glycemic goals are difficult to achieve and sustain in clinical practice. The Renin Angiotensin System Study (RASS) showed that renin-angiot...

Descripción completa

Detalles Bibliográficos
Autores principales: Harindhanavudhi, Tasma, Mauer, Michael, Klein, Ronald, Zinman, Bernard, Sinaiko, Alan, Caramori, M. Luiza
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Diabetes Association 2011
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3142059/
https://www.ncbi.nlm.nih.gov/pubmed/21715517
http://dx.doi.org/10.2337/dc11-0476

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3142059/
https://www.ncbi.nlm.nih.gov/pubmed/21715517
http://dx.doi.org/10.2337/dc11-0476

Ejemplares similares